Background: Many patients with cancer involving the respiratory system suffer from the frequent recurrence of significant, submassive hemoptysis, which may result in invasive procedures, hospital stays, and a reduction in quality of life. Currently, there are no widely accepted noninvasive therapeutic options. Few case studies have looked at the benefit of tranexamic acid (TXA) as a noninvasive therapy in the treatment of hemoptysis.

Methods: A patient with an invasive airway malignancy presented to the emergency department with substantial hemoptysis. A nebulized TXA solution was used as a noninvasive therapy to control the hemorrhage.

Results: The patient's hemoptysis resolved fifteen minutes after the nebulized TXA therapy was initiated. There were no known adverse events.

Conclusion: Nebulized TXA seems to be a safe, effective, and noninvasive method for controlling, or at least temporizing, hemoptysis in select patients. Nebulized TXA may be useful as a palliative therapy for chronic hemoptysis and as a tool in the acute stabilization of hemoptysis.

Download full-text PDF

Source
http://dx.doi.org/10.1089/jpm.2015.0167DOI Listing

Publication Analysis

Top Keywords

nebulized txa
16
noninvasive therapy
12
tranexamic acid
8
hemoptysis
7
nebulized
5
noninvasive
5
therapy
5
txa
5
nebulized tranexamic
4
acid noninvasive
4

Similar Publications

Background: Hemoptysis, the expectoration of blood from the lower respiratory tract, varies in severity and necessitates effective management to mitigate morbidity. Traditional treatments include bronchial artery embolization and pharmacological approaches. Tranexamic acid (TXA), an antifibrinolytic agent known for its efficacy in reducing bleeding during surgery and trauma, is being explored for its efficacy in treating Hemoptysis via both intravenous and inhalational routes.

View Article and Find Full Text PDF
Article Synopsis
  • Pulmonary hemorrhage is a serious condition that causes blood to leak into the lungs, leading to severe breathing issues, and nebulized tranexamic acid (TXA) shows promise as a treatment option due to its targeted effects and fewer side effects.
  • A thorough search of multiple research databases revealed studies on nebulized TXA for pulmonary hemorrhage, including data from two randomized controlled trials, six case series, and nine case reports.
  • The findings indicate that nebulized TXA effectively manages bleeding with a dosage of 500 mg/5 ml given 3-4 times daily, showing safety with minimal side effects, mainly local reactions that are easily treated.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the use of nebulized tranexamic acid (TXA) for treating post-tonsillectomy bleeding (PTB), a common complication leading to emergency department visits.
  • By systematically reviewing nine studies, the researchers assessed the effectiveness and safety of nebulized TXA, finding a lower reoperation rate for those treated with TXA compared to those who weren't.
  • The results suggest that nebulized TXA is a safe and effective treatment for PTB, but more extensive research is needed to confirm these findings.
View Article and Find Full Text PDF

Tranexamic acid (TXA) is a medication used to treat or prevent excessive blood loss due to certain medical conditions. It has a low side effect profile and is safe to administer in most instances. Anaphylaxis cases due to intravenous TXA have been reported in the literature.

View Article and Find Full Text PDF

Objectives: The use of nebulized tranexamic acid (TXA) in massive pulmonary hemorrhage is well-described. Published utilization in post-tonsillectomy bleeding (PTB) is limited to a single case. This study examines whether TXA resulted in change of operative intervention necessity and narcotic utilization.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!